Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Advanced Micro Devices

Ford Motor Company

Iveda Solutions Inc

Mullen Automotive

NVIDIA

Twitter

Veru

Exela Technologies

Trading volume is a simple way to measure how much of a security is being traded over a period of time. A high trading volume indicates high buying pressure if the stock is moving higher, or high selling pressure if the stock is moving lower.

These 8 Stocks Are Seeing Massive Volume Today

Hoth Therapeutics (HOTH) stock is rising higher on Monday after the biopharmaceutical company provided an update on HT-KIT. The post Why Is Hoth Therapeutics (HOTH) Stock Skyrocketing 110% Today?

Why Is Hoth Therapeutics (HOTH) Stock Skyrocketing 110% Today?

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are surging after announcing development updates for its novel cancer therapeutic, HT-KIT. Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on.

Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hours

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 125.5% at $1.38 after the company said its mRNA frame-shifting therapeutic proved effective against aggressive cancer cells. Hoth says treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells.

Why Hoth Therapeutics Shares Are Rising

AIM ImmunoTech Inc

Genocea Biosciences

What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model. Orphan Drug status granted, successfully completed API manufacturing feasibility NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced a development updates for its novel cancer therapeutic, HT-KIT.

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells

Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic NEW YORK , April 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced the company will be presenting at the BIO International Convention taking place June 13 - 16, 2022 in San Diego, California. Dr. Stefanie Johns, Chief Scientific Officer, will be presenting an overview of the Hoth Therapeutics pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's disease therapeutic under development.

Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention

NEW YORK, March 22, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) on March 11, 2022. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting.

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance

NEW YORK , March 11, 2022 /PR Newswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced the U.S. Food and Drug Administration (FDA) designated HT-KIT, a new molecular entity, as an Orphan Drug for the treatment of mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting.

Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.

Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients

NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California. Dr. Carla Yuede, lead researcher on the HT-ALZ sponsored research agreement with Washington University , will be the primary author presenting the data.

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

NEW YORK , Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD.

Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

AbbVie

Biogen

Bristol-Myers

Johnson & Johnson

Longeveron

Pfizer

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

These Emerging Biotechs Could Beat Alzheimer's Disease

Investors in Hoth Therapeutics and HOTH stock have seen their investment go parabolic today on a key update for one of the company's drugs. The post HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today?

HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today?

The stock price of Hoth Therapeutics Inc (NASDAQ: HOTH) increased by over 120% during intraday trading today. This is why it happened.

Hoth Therapeutics Stock (NASDAQ: HOTH): Why The Price Surged Today

Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.  HT-ALZ is in development under the 505(b)(2) regulatory pathway for the treatment of dementia-related to Alzheimer's disease (AD).

Why Hoth Therapeutics Stock Is Soaring Today?

Immix Biopharma

Plus Therapeutics Inc

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, resulting in apoptosis of neoplastic mast cells.

Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics ("Zylö") to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Hoth's CEO, Robb Knie, stated "The licensing of HT-005 back to Zylö after proving its efficacy and safety in animals is a win-win for both companies.

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics

Hoth Therapeutics Inc (NASDAQ: HOTH) has agreed to license its cannabinoid therapeutic, HT-005, for lupus patients back to Zylö Therapeutics. What Happened: In August 2019, Hoth Therapeutics and Zylö Therapeutics agreed to jointly develop an endocannabinoid-based treatment for cutaneous lupus erythematosus (CLE), a lupus subtype that affects the skin.

EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zylö

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment and dosing has begun for the second cohort in its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema. "We are excited to have reached this pivotal milestone in our BioLexa development program to begin dosing adult patients," stated Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics.

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way

NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC State") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers. The research will be led by Dr. Glenn Cruse, Assistant Professor, and will focus on characterizing the HT-KIT dose and dosing frequency for treatment of aggressive mastocytosis and mast cell neoplasms using humanized tumor mouse models.

Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT

The biopharmaceutical industry is a high-risk, high-reward industry where stocks soar and plummet with the approval or rejection of drugs. In addition, a strict regulatory framework must govern this sector in order to prevent scams and ineffective or harmful treatments, so most companies have to undertake years of research and extended trials to get a product approved for commercial production.

Hoth Therapeutics: Emerging Biotech With a Diversified Pipeline

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT. HT-KIT is a new molecular entity (NME) morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)) and anaphylaxis.

Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic

News for Hoth Therapeutics Stock (HOTH)